Original ArticleIASLC Staging Committee ArticleThe IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification
IASLC Staging Committee Article
Under an Elsevier user license
open archive
Keywords
Lung cancer
Non–small cell lung cancer
TNM classification
Lung cancer staging
Multiple tumors
Cited by (0)
Discloure: Dr. Nicholson reports personal fees from Merck, Bristol Myers Squib, Roche, AstraZeneca, Pfizer, Boehringer Ingelheim, Eli Lilly, and Novartis outside the submitted work. Dr. Donington reports serving on the board of and receiving nonfinancial support from KCI Inc. outside the submitted work. Dr. Asamura reports lecture fees from Johnson and Johnson and Covidien Japan and an advisory fee from Covidien Japan. The remaining authors declare no conflict of interest.
© 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.